Paper Details
- Home
- Paper Details
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Author: BrandesAlba A, ClementPaul M, GolfinopoulosVassilis, GorliaThierry, IdbaihAhmed, Le RhunEmilie, OppongFelix Boakye, PlattenMichael, PreusserMatthias, TaphoornMartin Jb, WellerMichael, WickWolfgang, van den BentMartin
Original Abstract of the Article :
BACKGROUND: Thrombocytopenia represents the main cause of stopping alkylating chemotherapy for toxicity. Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma. METHODS: We performed a retrospecti...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.ejca.2022.10.006
データ提供:米国国立医学図書館(NLM)
Thrombocytopenia: A Hidden Obstacle in Glioblastoma Treatment
Glioblastoma, a type of brain tumor, is a challenging condition that can feel like navigating a desert of uncertainty. This study explores the impact of thrombocytopenia, a condition characterized by low platelet count, on the treatment of recurrent glioblastoma. The researchers are searching for ways to overcome the obstacles that can hinder treatment effectiveness, much like finding a way to cross a treacherous desert canyon.
The study found that thrombocytopenia is a significant obstacle in the treatment of recurrent glioblastoma. It's like encountering a hidden canyon that blocks the path forward. The researchers also found that thrombocytopenia can lead to treatment delays and dose reductions, ultimately affecting the effectiveness of treatment.
Overcoming the Canyon: Managing Thrombocytopenia in Glioblastoma
This research highlights the importance of managing thrombocytopenia in patients with recurrent glioblastoma. It's like finding a way to cross a treacherous canyon, ensuring a safe and effective passage through the desert of treatment.
The study emphasizes the need for strategies to mitigate thrombocytopenia, allowing for better treatment delivery and improving outcomes for patients. It's like finding a hidden bridge that allows for a smoother journey through the desert, leading to greater chances of success.
Dr.Camel's Conclusion
This study shines a light on the challenges of thrombocytopenia in recurrent glioblastoma treatment. It's like encountering a hidden canyon that can hinder progress. The researchers are working to find ways to overcome this obstacle, paving the way for more effective treatment and improved outcomes for these patients.
Date :
- Date Completed 2022-12-23
- Date Revised 2023-03-13
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.